Christopher Springall

Christopher Springall currently serves as an Independent Pre-clinical Consultant at CJS Scientific, where he leverages over three decades of expertise in toxicologic pathology and toxicology to guide clients through the complex landscape of early-stage pharmaceutical development. In his role, Christopher specializes in providing strategic insights on pre-Phase I safety assessments, designing robust preclinical packages, and advising on first-in-man dose selection and dose escalation strategies. His deep understanding of toxicologic pathology enables him to identify potential safety signals early, ensuring that clients’ investigational new drug (IND) submissions are comprehensive and scientifically sound.

A key aspect of Christopher’s work involves conducting thorough due diligence for biotech and pharmaceutical companies, assessing the safety profiles of novel compounds, and preparing regulatory submissions that meet stringent international standards. His expertise extends to offering expert opinions on toxicology and pathology issues, representing clients in discussions with regulatory authorities such as the FDA, EMA, and PMDA, and navigating complex regulatory pathways.

With a broad skill set encompassing clinical development, preclinical safety, in vitro toxicology, and biopharmaceuticals, Christopher is adept at integrating multidisciplinary data to inform decision-making. His extensive network across Europe, the USA, and Japan allows him to stay at the forefront of industry trends and regulatory expectations. Whether advising on Phase I trial design, biotechnological innovations, or regulatory strategy, Christopher Springall’s insights are instrumental in advancing promising medicines from preclinical research to clinical success.